Biotech Startups

c-lecta introduces its management team and staff of over 130 employees. The page focuses on the company's personnel rather than describing its products or services in detail.

1 investor

Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for patients with autoimmune diseases. Its CABA platform and lead CARTA program center on rese-cel, an investigational CD19-CAR T cell therapy being evaluated in trials across rheumatology, neurology, and dermatology.

1 investor

CABB Group is a contract development and manufacturing company (CDMO) specializing in the production of customized, complex molecules for crop sciences, life sciences, and performance materials industries. The company offers custom fine chemical manufacturing services as well as fine chemicals including reagents, building blocks, and advanced intermediates for downstream applications.

1 investor

CaCO₃ Biotech recovers whole mollusk shells that are byproducts of Quebec's seafood industry and cultures nacre (mother-of-pearl) from them, turning marine coproducts otherwise destined for landfill into usable materials. It supplies natural ingredients for cosmetics, biomaterials, jewelry, and decorative or craft applications, positioning itself as the first company to commercialize such products in North America, with operations in the Gaspésie region.

1 investor

A company working to convert a popular oral contraceptive from prescription to over-the-counter status to increase contraceptive access.

1 investor

Cadent Therapeutics was a Cambridge, Massachusetts-based neuroscience company developing clinical-stage therapies for neuropsychiatric disorders including schizophrenia, movement disorders, and treatment-resistant depression. The company was acquired by Novartis in 2021.

1 investor

Cadila Pharmaceuticals is one of India's largest privately held pharmaceutical companies engaged in the discovery, development, and manufacturing of affordable generic and innovative medicines for patients globally. The company operates across 100 countries in seven regions, with a focus on making quality healthcare accessible and cost-effective.

1 investor

Cadmus Animal Health develops an immunotherapeutic to treat chronic periodontal disease caused by the bacterium Porphyromonas in companion animals. It operates in the veterinary/animal health biotech sector.

1 investor

Caidya provides clinical trial management solutions designed for pharmaceutical and biotech companies seeking to improve trial efficiency and patient outcomes through integrated, patient-centric approaches.

1 investor

Cajal Therapeutics develops novel therapies through translating scientific advances into treatments for patients. The company is led by a team of experienced scientists and operators focused on drug discovery and development.

1 investor

1 investor

Calder Biosciences develops protein-based subunit vaccines using its 3D-Vaxlock technology, which uses dityrosine crosslinking to lock immunogens into the shape they hold on a virus surface for improved antibody responses. Its engineered immunogens aim to offer better safety, efficacy, thermostability, and reduced cold chain requirements against infectious diseases.

1 investor

CALDRE is a Switzerland-based biotech spin-out developing liver-directed GalNAc-siRNA therapeutics, including its claudin-3 targeting candidate ClagalsiR, to restore bile flow and prevent fibrosis. It aims to treat cholestatic and fibrotic liver diseases such as primary sclerosing cholangitis and primary biliary cholangitis and reduce the need for liver transplantation.

1 investor

Calico is a research and development company studying the biology of aging and translating those insights into potential medicines for age-related diseases. It combines basic research, computational biology and machine learning, and drug development to advance early- and clinical-stage compounds.

1 investor

Calla Lily Clinical Care is a women's health company developing intravaginal drug delivery products based on its proprietary Callavid platform device, targeting IVF, prevention of preterm birth and miscarriage, delivery of live biotherapeutics to restore the vaginal microbiome, and biomarker sample collection for diagnostics such as endometriosis. Its FDA-cleared device technology serves the women's health and medical device market.

1 investor

1 investor

Calycia Bioscience is a biotechnology company developing engineered macrophage cell therapies delivered locally into the brain to target aggressive solid tumors of the central nervous system. Its pipeline focuses on glioblastoma and melanoma brain metastasis within CNS oncology.

1 investor

Calyxha is a biotech company developing novel small molecule anti-inflammatory drugs for multiple inflammatory diseases. Its lead product, CAL-4, is in preclinical development as an alternative to corticosteroids for asthma.

1 investor

Cambrex provides pharmaceutical supply chain management and manufacturing services focused on supply chain resilience through dual sourcing and contingency planning to ensure reliable product delivery during disruptions.

1 investor

Cambridge Nucleomics develops a single-molecule RNA counting "nanoarray" assay based on solid-state nanopore and DNA nanotechnology for diagnostic testing. The company applies its technology to RNA biology and microbiology-based diagnostics.

1 investor

1 investor

The company develops a 6-base sequencing platform (duet evoC) that simultaneously profiles methylation (5mC, 5hmC), genetic variants, and fragmentomics from a single cfDNA sample. Its multi-modal liquid biopsy technology is aimed at biomarker discovery and cancer detection for genomics and life sciences research.

1 investor

Cambridge Vision Technology develops diagnostic hardware and software for detecting Alzheimer's disease and other neurodegenerative conditions through retinal imaging and biomarker analysis. The company serves healthcare providers seeking early, non-invasive screening tools for preclinical Alzheimer's disease risk.

1 investor

novoLUX develops science-based skincare using LNP3, a patented triple-layer lipid nanoparticle technology that delivers peptides, exosomes, and PDRN with sustained release. The products target specific skin concerns such as acne-prone skin, post-procedure repair, dryness, hyperpigmentation, fine lines, and radiance.

1 investor